title: Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
abstract: BACKGROUND
  Thirty-three patients (median age 52; range 26-60) with acute myeloblastic leukemia (AML) were included in a pilot study of allogeneic stem cell transplantation (Allo-SCT) following a reduced-intensity conditioning (RIC).
  
  
  METHODS
  Patients achieving first complete remission (CR1) were selected for their high-risk clinical and/or leukemic features. All patients received two courses of consolidation chemotherapy including one high-dose cytarabine course. Among them, 13 patients in addition received a high-dose melphalan course followed by autologous SCT. Then, all patients received an RIC Allo-SCT combining fludarabine, busulfan, and antithymocyte globulin.
  
  
  RESULTS
  All patients engrafted had cumulative incidences of Gluksberg System Grade 2 acute and chronic graft-versus-host-disease (GVHD) of 24 (9-39%) and 64 (48-80%), respectively. Three patients died from nonrelapse causes (NRD) (cumulative incidence: 9%, 95% confidence interval (CI): 0-19) and 6 relapsed (cumulative incidence: 18%, 95% CI: 5-31). With a median follow-up of 18 months (range 7-52) after Allo-SCT, 26 patients are alive, of whom 24 remained in CR1 for a 2-year overall survival and leukemia-free survival (LFS) probabilities of 79 (range 61-90%) and 76 (range 59-87%), respectively. In a 'landmark' analysis starting on Day 100, the occurrence of chronic GVHD was associated with a lower relapse rate (0% vs. 44%: P = 0.007) and improved outcome (LFS; 95% vs. 53%, P = 0.007; overall survival, 95% vs. 61%, P = 0.05).
  
  
  CONCLUSIONS
  We conclude that the sequential combination of intensive chemotherapy and allogeneic immunotherapy might offer relatively low NRD and leukemia relapse rates even in high-risk patients.
authors.affiliation: Unité de Transplantation et de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France. uttc@marseille.fnclcc.fr
authors.forename: Didier P
authors.initials: DP
authors.lastname: Blaise
authors.forename: Jean
authors.initials: J
authors.lastname: Michel Boiron
authors.forename: Catherine
authors.initials: C
authors.lastname: Faucher
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
authors.forename: Valerie-Jeanne
authors.initials: VJ
authors.lastname: Bardoux
authors.forename: Virginie
authors.initials: V
authors.lastname: Perreau
authors.forename: Diane
authors.initials: D
authors.lastname: Coso
authors.forename: Arnaud
authors.initials: A
authors.lastname: Pigneux
authors.forename: Norbert
authors.initials: N
authors.lastname: Vey
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012074:Remission Induction; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000379:methods*; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome